Omeros (NASDAQ:OMER) Research Coverage Started at Rodman & Renshaw

Rodman & Renshaw started coverage on shares of Omeros (NASDAQ:OMER) in a report released on Thursday, Marketbeat.com reports. The brokerage issued a buy rating and a $9.00 price target on the biopharmaceutical company’s stock.

Separately, StockNews.com cut shares of Omeros from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $9.00.

Omeros Trading Down 2.9 %

NASDAQ OMER opened at $6.75 on Thursday. Omeros has a 1 year low of $1.38 and a 1 year high of $7.51. The company’s 50 day simple moving average is $4.14 and its two-hundred day simple moving average is $4.10.

Institutional Trading of Omeros

Several institutional investors and hedge funds have recently made changes to their positions in OMER. BNP Paribas Financial Markets raised its position in shares of Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 7,016 shares in the last quarter. MML Investors Services LLC raised its position in shares of Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 3,000 shares in the last quarter. SPC Financial Inc. purchased a new stake in shares of Omeros during the 3rd quarter valued at $77,000. SG Americas Securities LLC purchased a new stake in shares of Omeros during the 3rd quarter valued at $80,000. Finally, Oppenheimer & Co. Inc. purchased a new stake in shares of Omeros during the 1st quarter valued at $85,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.